At the end of the latest market close, Actinium Pharmaceuticals Inc. (ATNM) was valued at $0.31. In that particular session, Stock kicked-off at the price of $0.32 while reaching the peak value of $0.40 and lowest value recorded on the day was $0.32. The stock current value is $0.36.
Recently in News on June 19, 2020, Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common stock equivalent). The aggregate gross proceeds from this offering are approximately $25.0 million, before deducting placement agent fees and other estimated offering expenses payable by Actinium. You can read further details here
Actinium Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $0.6200 on 06/10/20, with the lowest value was $0.1570 for the same time period, recorded on 04/22/20.
Actinium Pharmaceuticals Inc. (ATNM) full year performance was 43.28%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Actinium Pharmaceuticals Inc. shares are logging -42.60% during the 52-week period from high price, and 126.69% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.16 and $0.62.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 19231160 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Actinium Pharmaceuticals Inc. (ATNM) recorded performance in the market was 63.48%, having the revenues showcasing 88.51% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 147.80M, as it employees total of 25 workers.
The Analysts eye on Actinium Pharmaceuticals Inc. (ATNM)
During the last month, 0 analysts gave the Actinium Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.2459, with a change in the price was noted +0.1310. In a similar fashion, Actinium Pharmaceuticals Inc. posted a movement of +58.25% for the period of last 100 days, recording 10,620,157 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ATNM is recording 0.13 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.03.
Technical rundown of Actinium Pharmaceuticals Inc. (ATNM)
Raw Stochastic average of Actinium Pharmaceuticals Inc. in the period of last 50 days is set at 40.77%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 15.43%. In the last 20 days, the company’s Stochastic %K was 9.37% and its Stochastic %D was recorded 13.75%.
Considering, the past performance of Actinium Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 63.48%. Additionally, trading for the stock in the period of the last six months notably improved by 48.29%, alongside a boost of 43.28% for the period of the last 12 months. The shares increased approximately by -1.85% in the 7-day charts and went down by 22.72% in the period of the last 30 days. Common stock shares were driven by 88.51% during last recorded quarter.